Psychedelic Science Institute Launches TRIP Clinics in LA for Mental Health

Psychedelic Science Institute Launches TRIP Clinics in Los Angeles

On July 1, 2025, the Psychedelic Science Institute (PSI) officially launched its innovative clinical trial and treatment network with the inauguration of two new clinics in Santa Monica and Hollywood, California. Dubbed the TRIP Clinics (Treatment Research in Psychedelics), these facilities serve as critical hubs for both industry-driven and investigator-led clinical trials focusing on psychedelic-assisted therapies that target various mental health and neuroscience conditions.

The establishment of PSI comes as a result of the strategic merger between the Pacific Neuroscience Institute's TRIP Center and the California Center for Psychedelic Therapy. Together, this collaboration harnesses over 30 years of combined expertise in neuroscience, psychotherapy, and psychedelic research. Notably, the founding team has successfully enrolled over 90 patients across ten clinical trials aimed at addressing ailments such as depression, anxiety, PTSD, and alcohol use disorder. Furthermore, they have facilitated more than 10,000 ketamine-assisted therapy sessions to date.

Dr. Daniel Kelly, the President and CEO of PSI, emphasized the transformative potential of psychedelics in contemporary psychiatry, stating, "As neuroplastogens, psychedelics may offer the greatest potential in decades to transform psychiatry and neuroscience. Our TRIP Clinics will rigorously assess these paradigm-shifting treatments in collaboration with industry and academic partners."

With initial philanthropic funding amounting to $1.2 million, PSI embarks on a dual mission: to fast-track the development of FDA-approved psychedelic treatments and to create a scalable, accessible model for transformative mental health care. The clinical trials undertaken at PSI will explore the benefits of substances including psilocybin, LSD, MDMA, and 5-MeO-DMT, while also providing ketamine-assisted psychotherapy in accordance with established protocols.

Brooke Balliett, the Chief Operating Officer of PSI, expressed enthusiasm about the launch, stating, "We are thrilled to launch PSI as a partnership of two of California's most experienced and long-standing psychedelic research and care clinics. We look forward to expanding our services across our diverse Los Angeles communities and beyond.”

In alignment with their mission, PSI is also committed to public education and clinician training through the Psychedelic Innovation Fund, a nonprofit initiative aimed at laying the groundwork for the responsible and ethical growth of the psychedelic field. Dr. Keith Heinzerling, the Chief Medical Science Officer at PSI, reaffirmed the organization’s readiness to contribute meaningfully to the current psychedelic research landscape: "PSI is built to meet this moment in psychedelic research. We bring real-world experience, a highly skilled clinical operations team, and a deep commitment to scientific rigor and patient safety."

To explore partnership opportunities regarding clinical trials or to learn more about the programs and research, interested parties can visit www.psychedelicsci.com. For media inquiries, Greg Kearns can be reached at 410-409-8913 or via email at [email protected].

The launch of the PSI TRIP Clinics represents a significant milestone in the evolution of mental health care, combining cutting-edge research with compassionate patient treatment to pioneer the future of psychedelic-assisted therapies.